Vor Biopharma Inc. (NASDAQ:VOR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have received an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $43.3750.

A number of equities analysts recently issued reports on VOR shares. Weiss Ratings raised Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday, August 11th. Wedbush raised their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $25.05 on Thursday. The business has a 50-day moving average of $21.41 and a two-hundred day moving average of $17.19. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $49.95.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Equities research analysts anticipate that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently bought and sold shares of VOR. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Vor Biopharma in the 3rd quarter valued at about $230,000. BNP Paribas Financial Markets boosted its position in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at about $304,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).